We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aspen Pharmacare (APNHY - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aspen Pharmacare is a member of our Medical group, which includes 915 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, APNHY has returned 44.6% so far this year. In comparison, Medical companies have returned an average of 3.2%. This shows that Aspen Pharmacare is outperforming its peers so far this year.
Another stock in the Medical sector, Corcept Therapeutics (CORT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 232.3%.
Over the past three months, Corcept Therapeutics' consensus EPS estimate for the current year has increased 249.3%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, a group that includes 12 individual stocks and currently sits at #51 in the Zacks Industry Rank. Stocks in this group have gained about 7.3% so far this year, so APNHY is performing better this group in terms of year-to-date returns.
Corcept Therapeutics, however, belongs to the Medical - Drugs industry. Currently, this 137-stock industry is ranked #165. The industry has moved -4% so far this year.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Corcept Therapeutics. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aspen Pharmacare (APNHY - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aspen Pharmacare is a member of our Medical group, which includes 915 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, APNHY has returned 44.6% so far this year. In comparison, Medical companies have returned an average of 3.2%. This shows that Aspen Pharmacare is outperforming its peers so far this year.
Another stock in the Medical sector, Corcept Therapeutics (CORT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 232.3%.
Over the past three months, Corcept Therapeutics' consensus EPS estimate for the current year has increased 249.3%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, a group that includes 12 individual stocks and currently sits at #51 in the Zacks Industry Rank. Stocks in this group have gained about 7.3% so far this year, so APNHY is performing better this group in terms of year-to-date returns.
Corcept Therapeutics, however, belongs to the Medical - Drugs industry. Currently, this 137-stock industry is ranked #165. The industry has moved -4% so far this year.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Corcept Therapeutics. These stocks will be looking to continue their solid performance.